Price
$38.04
Increased by +2.05%
Dollar volume (20D)
71.85 M
ADR%
3.99
Earnings report date
Nov 5, 2025
Shares float
158.55 M
Shares short
15.18 M [9.57%]
Shares outstanding
186.93 M
Market cap
6.97 B
Beta
1.16
Price/earnings
N/A
20D range
34.00 38.60
50D range
34.00 40.70
200D range
29.17 62.40

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.

Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C).

The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1.

Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Reported date EPSChange YoY EstimateSurprise
Aug 6, 25 -1.31
Decreased by -61.73%
-1.12
Decreased by -16.96%
May 6, 25 -1.13
Decreased by -61.43%
-0.75
Decreased by -50.67%
Feb 24, 25 -1.12
Increased by +1.75%
-0.96
Decreased by -16.12%
Nov 6, 24 -0.94
Increased by +5.05%
-0.89
Decreased by -5.62%
Aug 7, 24 -0.81
Increased by +11.96%
-0.77
Decreased by -5.19%
May 8, 24 -0.70
Increased by +2.78%
-0.75
Increased by +6.67%
Feb 26, 24 -1.14
Decreased by -80.95%
-0.88
Decreased by -29.55%
Nov 6, 23 -0.99
Decreased by -13.79%
-1.01
Increased by +1.98%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 0.00
Decreased by N/A%
-247.79 M
Decreased by -85.98%
Decreased by N/A%
Decreased by N/A%
Mar 31, 25 0.00
Decreased by N/A%
-213.42 M
Decreased by -83.97%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 261.59 M
Increased by +35.15 K%
-194.57 M
Decreased by -20.45%
Decreased by -74.38%
Increased by +99.66%
Sep 30, 24 0.00
Decreased by N/A%
-156.29 M
Decreased by -44.13%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by -100.00%
-133.23 M
Decreased by -35.54%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by -100.00%
-116.00 M
Decreased by -70.35%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 742.00 K
Decreased by -95.16%
-161.54 M
Decreased by -185.87%
Decreased by -21.77 K%
Decreased by -5.81 K%
Sep 30, 23 0.00
Decreased by -100.00%
-108.43 M
Decreased by -47.87%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY